Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.

Pigment epithelium-derived factor (PEDF) is a multifunctional protein with antiangiogenic, antioxidative, and anti-inflammatory properties. PEDF is involved in the pathogenesis of diabetic retinopathy, but its direct role in the kidneys remains unclear. We hypothesize that a PEDF fragment (P78-PEDF) confers kidney protection in diabetic nephropathy (DN). The localization of the full-length PEDF protein were determined in DBA mice following multiple low doses of streptozotocin. Using immunohistochemistry, PEDF was localized in the kidney vasculature, interstitial space, glomeruli, tubules, and renal medulla. Kidney PEDF protein and mRNA expression were significantly reduced in diabetic mice. Continuous infusion of P78-PEDF for 6 wk resulted in protection from diabetic neuropathy as indicated by reduced albuminuria and blood urea nitrogen, increased nephrin expression, decreased kidney macrophage recruitment and inflammatory cytokines, and reduced histological changes compared with vehicle-treated diabetic mice. In vitro, P78-PEDF blocked the increase in podocyte permeability to albumin and disruption of the actin cytoskeleton induced by puromycin aminonucleoside treatment. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in early phase diabetic renal injury.

[1]  E. Abdel-Rahman,et al.  Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches , 2012, Journal of General Internal Medicine.

[2]  M. Okusa,et al.  Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. , 2011, American journal of physiology. Renal physiology.

[3]  S. Morris,et al.  Arginase-2 Mediates Diabetic Renal Injury , 2011, Diabetes.

[4]  H. Velázquez,et al.  Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes , 2011, Diabetologia.

[5]  A. Gvritishvili,et al.  Codon Preference Optimization Increases Heterologous PEDF Expression , 2010, PloS one.

[6]  K. Reidy,et al.  Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. , 2010, Kidney international.

[7]  J. Tombran-Tink,et al.  PEDF in angiogenic eye diseases. , 2010, Current molecular medicine.

[8]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[9]  J. Reutershan,et al.  Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. , 2009, Kidney international.

[10]  Yunyu Zhang,et al.  Validation of volume-pressure recording tail-cuff blood pressure measurements. , 2008, American journal of hypertension.

[11]  Ying Chen,et al.  Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[12]  A. Shoukas,et al.  Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis , 2008, Circulation research.

[13]  GH Tesch.  ROLE OF MACROPHAGES IN COMPLICATIONS OF TYPE 2 DIABETES , 2007, Clinical and experimental pharmacology & physiology.

[14]  Yuan Zhang,et al.  Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions , 2007, Proceedings of the National Academy of Sciences.

[15]  R. Gilbert,et al.  Effects on protein kinase C-β inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy , 2007 .

[16]  M. Nagata,et al.  Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  A. Brawanski,et al.  Expression of pigment-epithelium-derived factor during kidney development and aging , 2007, Cell and Tissue Research.

[18]  F. Ziyadeh,et al.  Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. , 2006, Journal of the American Society of Nephrology : JASN.

[19]  C. Barnstable,et al.  A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. , 2006, Experimental eye research.

[20]  S. Shankland,et al.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.

[21]  R. Mott,et al.  Salutary Effect of Pigment Epithelium–Derived Factor in Diabetic Nephropathy , 2006, Diabetes.

[22]  Liping Huang,et al.  Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. , 2006, American journal of physiology. Renal physiology.

[23]  Liping Huang,et al.  Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. , 2006, American journal of physiology. Renal physiology.

[24]  C. Barnstable,et al.  PEDF and the serpins: phylogeny, sequence conservation, and functional domains. , 2005, Journal of structural biology.

[25]  E. Ritz,et al.  Nephron number and renal risk in hypertension and diabetes. , 2005, Journal of the American Society of Nephrology : JASN.

[26]  C. Barnstable,et al.  Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential , 2004, Progress in Retinal and Eye Research.

[27]  M. Madaio,et al.  Isolation, culture, and characterization of endothelial cells from mouse glomeruli. , 2004, Kidney international.

[28]  Jian-guo Ren,et al.  Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[30]  Lee Hebert,et al.  Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  C. Barnstable,et al.  Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. , 2003, Trends in molecular medicine.

[32]  L. Ellis,et al.  Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. , 2000, Anti-cancer drug design.

[33]  M. Cooper,et al.  Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.

[34]  J. Tombran-Tink,et al.  PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.

[35]  C. Barnstable,et al.  Pigment Epithelium-Derived Factor ( PEDF ) Peptide Eye Drops Reduce Inflammation , Cell Death and Vascular Leakage in Diabetic Retinopathy in Ins 2 Akita Mice , 2012 .

[36]  Ross Ward,et al.  United States Renal Data System , 2011 .

[37]  J. Sedor,et al.  Activation of adenosine 2A receptors preserves structure and function of podocytes. , 2008, Journal of the American Society of Nephrology : JASN.

[38]  Yuan Zhang,et al.  Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. , 2007, American journal of physiology. Renal physiology.

[39]  R. Harris,et al.  Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. , 2006, Journal of the American Society of Nephrology : JASN.

[40]  Ying Chen,et al.  Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. , 2005, Diabetes.

[41]  L. Agodoa,et al.  United States Renal Data System (USRDS). , 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[42]  Y. Tomino,et al.  Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. , 1993, Clinical immunology and immunopathology.